Enlivex 2025: The Balance Sheet Moved Into RAIN, but the Real Proof Still Sits in the Knee Trial and in Liquidity

Company Overview

At first glance, Enlivex looks like one of the sharpest transformations in the market this year: a company that finished 2025 with no revenue from operations, yet reported $1.236 billion of net income, $1.935 billion of equity, and a balance sheet that looks much closer to a digital-asset treasury vehicle than to a biotech company. That is true at the accounting level. It is not the heart of the story. The heart of the story is that Enlivex is still managed and defined as a single operating segment focused on Allocetra, and the business still has to prove itself clinically.

What is working now? The knee-osteoarthritis program produced an interesting efficacy signal in 2025 in the age 60-plus population, and in March 2026 the FDA cleared the IND for the Phase IIb trial in the United States. That is not revenue, but it is real progress. At the same time, management replaced the classic biotech question of “how much cash is left” with a huge layer of RAIN tokens and a large option to buy more at a fixed price.

What is still messy? At year-end 2025 the company had only $5.755 million of cash and short-term deposits, while 99.51% of total assets sat in RAIN and in the RAIN option. The company itself notes that selling RAIN produces USDT first and only then needs to be converted into U.S. dollars. So even though the balance sheet expanded dramatically, immediate liquidity remained narrow. After the balance sheet date, the story also picked up debt: on March 23, 2026 the company received $19 million of funding in exchange for a $21 million senior secured convertible note, secured by part of its digital-asset accounts.

That is why the active bottleneck is no longer fair value but accessible value. For the Enlivex story to improve over the next few quarters, three things need to happen together: the Phase IIb knee trial needs to launch cleanly, the liquidity layer needs to remain sufficient even after the new note and its repayment schedule, and the company needs to show that the gap between fair value on paper and value actually reachable by common shareholders can narrow.

There is also a practical actionability constraint. On April 6, 2026 local daily turnover was only about NIS 65 thousand, and the company has already said that its last trading day on the TASE is expected to be April 23, 2026, with delisting expected around April 26, 2026. In other words, Enlivex is not just a clinical and balance-sheet story. It is also becoming a story about a trading structure that is moving away from the local market.

The right economic map for Enlivex at the end of 2025 looks like this:

Events and Triggers

The clinical trigger

The real positive development in 2025 did not sit on the balance sheet. It sat in the knee program. In the Phase IIa stage of the moderate-to-severe knee-osteoarthritis trial, the company reported three-month data in August 2025 and six-month data in November 2025, with a positive correlation between age and the magnitude of effect. In the age 60-plus group, after three months, mean change in WOMAC Pain was negative 27.82 points versus negative 16.22 in placebo, WOMAC Function improved by negative 26.45 points versus negative 12.63 in placebo, and WOMAC Total improved by negative 26.43 points versus negative 13.75 in placebo.

That does not eliminate the road ahead. The proof point that can really change how the stock is read now sits in the global, randomized, double-blind Phase IIb trial that management is preparing. In March 2026 the FDA cleared the IND in the United States, and the company says it expects three-month topline data in the second quarter of 2027 and six-month topline data in the third quarter of 2027. In other words, 2026 and early 2027 remain a bridge period, not a commercialization year.

Another important point is that the company has narrowed its option set in practice. In sepsis, operational close-out of the study has been completed and management is now seeking collaboration or out-licensing for continued development. Two smaller Phase I studies, in basal-thumb osteoarthritis and psoriatic arthritis, were discontinued due to prioritization of the knee program. By contrast, long-term follow-up in end-stage knee osteoarthritis and a small TMJ trial remain ongoing. That is a picture of focus, but also of concentration.

The funding trigger

The event that changed the financial read was the digital-asset strategy adopted in November 2025. As part of that move, the company obtained an exclusive option to buy up to 278.182 billion RAIN tokens at $0.0033 per token. On December 1, 2025 it exercised part of the option and bought 3.03 billion tokens for $10 million. By year-end it already held 75.789 billion tokens at a fair value of $606.8 million, while the option itself was measured at a fair value of $1.709 billion.

After year-end, the story intensified. On March 23, 2026 the company exercised another 3.03 billion tokens for $10 million, and the option was extended through December 31, 2027. At the same time, it signed a senior secured convertible note with Lind Global Asset Management XIV with $21 million of principal, $19 million of funding, and approximately $18.7 million of net proceeds before expenses.

This matters because it both improves and burdens the story. It improves it because it brings in a new layer of cash and extends operating room. It burdens it because it turns part of the digital treasury from theoretical value into pledged collateral. In addition, the note is repayable in nine monthly installments of about $2.3 million starting on the 90th day after closing, and the company can choose to pay in cash plus 4% or in shares priced at 90% of the five lowest VWAPs during the prior 20 trading days. So the new money also creates a structure that can later become either a dilution path or a cash-use path.

The equity-market trigger

On March 15, 2026 the board approved a share-repurchase program of up to $20 million. That is an interesting signal, especially since management also said it views the stock as trading at a substantial discount to the value of its treasury and treasury-related assets. But the program does not obligate the company to repurchase any shares, has no expiration date, and sits on top of the same capital layer that also needs to support the clinical program and the new note.

At the same time, in early February 2026 shareholders approved both an increase in authorized share capital and a board authorization to carry out a reverse split at a ratio from 1-for-2 to 1-for-20 within 12 months. That does not mean a reverse split will happen immediately, but the new note says that if the stock trades below $1 for 30 trading days, the company must use best efforts to move forward with one. So even apparently supportive headlines such as buybacks sit next to structural mechanics that may push in the opposite direction.

Efficiency, Profitability and Competition

The most important point in 2025 is that reported profit does not really describe the business. Enlivex finished the year with $1.236 billion of net income, but operating loss still stood at $15.029 million versus $15.888 million in 2024. This was not a move from a loss-making biotech into a profitable operating company. It was a move from a loss-making biotech into a loss-making biotech whose balance sheet is marked to the fair value of RAIN and of the RAIN option.

Reported profit does not mean operating efficiency

At the expense level, there were useful changes, but they were far smaller than the numbers sitting above them. Research and development expense fell to $9.204 million from $10.623 million, down 13%, mainly because of a $1.29 million decline in clinical-study and material expenses, lower Allocetra dose manufacturing, a $215 thousand decline in depreciation, and a $178 thousand decline in share-based compensation. By contrast, general and administrative expense rose to $5.796 million from $4.913 million, up 18%, mainly because directors’ fees rose by $454 thousand and professional services rose by $615 thousand.

The right way to read this is not that the company has exited the loss zone. It is that operating burn became somewhat more disciplined, but not fundamentally different. That also fits the fact that the company continues to report zero revenue from operations.

Management itself tells you what the real business is

There is an accounting point here that is also an analytical one. The annual report explicitly says the company operates in a single segment focused on developing an off-the-shelf cell-therapy platform that restores macrophage homeostasis. The RAIN holdings and related instruments are managed as part of treasury and capital allocation, but do not constitute a separate operating segment because they do not generate recurring operating revenue, are not managed as a distinct business line, and are not reviewed that way for resource allocation.

That is the heart of the story. If both management and the auditors do not define the token layer as an operating business, investors should not confuse a larger balance sheet with a mature operating model.

Competition still sits at the proof stage

In a biotech company with no revenue, “competition” is not measured by market share. It is measured by the quality of the clinical signal, the speed of transition from one stage to the next, and the ability to finance the gap between the next trial and the next data point. On that front Enlivex did something sensible: it concentrated the story on the knee program, reduced weight on secondary programs, and moved sepsis toward a possible external partnering path.

The problem is that this sharper focus also deepens dependence. If the Phase IIb knee trial does not confirm the Phase IIa signal, there is currently no alternative operating engine that can carry the story. Even the smaller programs that remain active, in end-stage knee osteoarthritis and TMJ, are still early layers that cannot carry the central thesis by themselves.

Cash Flow, Debt and Capital Structure

This is a case where all-in cash flexibility is the right framework, not normalized cash generation. The reason is simple: Enlivex does not yet have a recurring revenue-producing business. The real question is how much cash and truly liquid assets remain after actual cash uses, and how dependent the company is on monetizing or pledging RAIN to get through the period until the next clinical proof point.

In 2025 cash used in operating activities was $10.416 million, an improvement from negative $13.008 million in 2024. Investing cash flow was negative $1.323 million and financing cash flow was positive $10.381 million. At year-end, cash, cash equivalents, and restricted cash totaled $2.373 million versus $3.731 million at the end of 2024. If you add short-term deposits, the company had only $5.755 million. That is the relevant number when asking how much immediate cash sits underneath all the RAIN headlines.

Real cash versus fair value

This is exactly where it is easy to get misled by the balance sheet. The company reports $1.935 billion of equity and roughly $1.7 billion of working capital, but those figures are driven almost entirely by RAIN and the RAIN option. At the end of 2025, RAIN and the option accounted for 99.51% of total assets, and the company itself says it is exposed to concentration in a single digital asset, to price volatility, and to liquidity risk because its holdings are large relative to trading volumes.

Another point readers may miss is that selling RAIN does not directly create U.S. dollars. The company states that RAIN is traded against USDT, and only then must the proceeds be converted into dollars. At the end of 2025 the company held no USDT. So even though fair value is very large, it is not the same thing as cash in the bank.

What the new note actually changes

After the balance sheet date, on March 23, 2026, the new note arrived. It sharpens everything that matters now:

The note also adds outside discipline. If market capitalization falls below $200 million, the company must maintain at least $5 million of Available Cash. If the stock stays below $1 for 30 trading days, the company must use best efforts to carry out a reverse split. These are not theoretical clauses. They show that the company did not just raise bridge financing. It also accepted a capital structure that responds directly to stock price and liquidity conditions.

Why the buyback does not solve the bottleneck

The up-to-$20 million buyback looks attractive at first glance. It also signals that management sees a discount between the stock price and the value of the treasury layer. But two things matter. The company is not obligated to repurchase even one share, and the same capital layer also has to support the clinical program and the new note. So the buyback is, at most, a signal of confidence. It is not a cash solution.

Outlook and Forward View

Before looking ahead, five non-obvious points need to stay front of mind:

1. The 2025 profit did not finance the clinical platform. It came almost entirely from marking RAIN and the RAIN option to fair value.
2. Even after the transformation of the balance sheet, management still sees the company as one clinical operating segment, not two equal businesses.
3. The runway through end-2027 now depends much less on cash already sitting in the bank and much more on the company’s ability to preserve liquidity around RAIN.
4. The March 2026 note solved immediate pressure, but also introduced a short repayment schedule, collateral, and dilution risk.
5. The next development that can genuinely change the quality of the story is not another token revaluation. It is Phase IIb in the knee program.

What must happen clinically

Enlivex is now in a clinical proof year, not a breakout year. If management stays on schedule, 2026 will be about launching Phase IIb and running the trial, while 2027 will bring the first two real test windows, at three months and six months. The market is likely to give only limited credit to anything other than concrete progress toward those data points.

The most important question is whether the age effect seen in Phase IIa survives in a broader trial. If it does, Enlivex will have much firmer ground under a focused clinical story. If it does not, the company will quickly return to the classic no-revenue biotech question: how much time and how much capital remain until the next thesis.

What must happen on the balance sheet

On the funding side, 2026 looks like a tight bridge year. The company says it has resources sufficient for at least the twelve months following the filing date and, under its current operating plan, approximately through the end of 2027. But it also says plainly that it will need additional financing beyond that point.

This is where the market can misread the balance sheet. Roughly $1.7 billion of working capital does not mean the company has $1.7 billion readily available to spend. It means that the option and the tokens were marked at high fair values. In practice, the company will need to manage the repayment calendar of the new note, preserve enough available liquidity, go through the TASE delisting, and potentially deal with reverse-split mechanics if the stock remains weak.

How the market may react

Management has chosen to frame the stock as trading at a discount to the value of the treasury and treasury-related assets. That framing is understandable, but incomplete. The market can easily keep a deep discount in place if it believes the value sits in a volatile, unhedged asset, has to move through USDT before becoming cash, and is already partly subject to lender collateral.

There is also a constructive path. If the knee trial progresses on time, if liquidity around RAIN remains sufficient without forcing aggressive selling, and if the new note does not push the company into structural dilution, the market may begin to believe that part of the on-paper value can become genuine time and breathing room for the clinical platform.

Risks

Digital concentration

This is the biggest risk in the report. At the end of 2025, RAIN and the RAIN option were 99.51% of assets. The company’s own sensitivity analysis shows that a hypothetical 10% move in the price of RAIN would have changed fair value by roughly positive $264.1 million or negative $262.2 million. That is extreme concentration even for an asset vehicle, and especially so for a biotech company.

Clinical risk

The company still has no revenue, no approved product, and no certainty that the knee program will turn into a commercialization path. Even if Phase IIa looked interesting, the move into Phase IIb is exactly where many biotech stories break down. Narrowing the other programs improves focus, but it also deepens dependence on one path.

Structural investor risk

The new note, the delisting from the TASE, and the reverse-split framework together create a real friction layer. Even the buyback, which sounds supportive, may in practice remain secondary if management decides that every available dollar is needed for clinical execution and note service.

Short Interest View

The short data do not describe a stock under extreme short attack, but they do describe a market that has become more skeptical since late 2025. On March 27, 2026 short interest was 1.37% of float, versus a sector average of 0.38%. SIR was 4.35 versus a sector average of 1.278. This is not a squeeze story, but it is clearly higher than the 0.36% to 0.42% float range seen in November and December 2025.

The right way to read this is moderate dissonance, not panic. On one hand, short interest is still not extreme in absolute terms. On the other hand, the sharp step-up after the adoption of the RAIN strategy suggests that part of the market does not yet buy the quick translation from fair value into accessible value.

Conclusions

Enlivex ended 2025 with a balance sheet that looks much stronger than the business sitting underneath it. That is not an accounting achievement to dismiss, but it is also not proof that the company solved either its funding question or its commercialization question. What holds the story together now is a combination of an interesting knee-clinical signal and a very large digital treasury. What blocks it is the fact that almost all of that value sits in one asset, while the operating business still has no revenue and now also carries a new debt layer.

Current thesis: Enlivex is still a no-revenue biotech, only now it has replaced a conventional cash box with a balance sheet built almost entirely around RAIN.

What changed from the older read: in 2025 the immediate-survival question stopped looking like “one more quarter of cash” and became a more complicated question of accessible value, token liquidity, collateral, and how all of that funds the knee trial.

Counter-thesis: if RAIN stays liquid, if the discount in the stock narrows at least partly, and if Phase IIb confirms the age 60-plus signal, the combination of a digital treasury and a focused clinical program could ultimately prove much stronger than it looks now.

What may change the market reading in the short to medium term: clean progress into Phase IIb, actual use or non-use of the buyback, and the way the company handles the new note without creating persistent dilution pressure.

Why this matters: because the gap between on-paper value and value actually accessible to common shareholders is the entire Enlivex story right now, not a footnote.

What must happen over the next 2 to 4 quarters for the thesis to strengthen: Phase IIb needs to launch, the liquidity layer needs to remain sufficient even under the note, and the company needs to move through the TASE delisting without adding new structural uncertainty. What would weaken the thesis is a combination of RAIN price weakness, renewed funding pressure, or delay in the clinical path.